Skip to main content

Advertisement

SpringerLink
Log in

Efficacy and safety of intravenous voriconazole and intravenous itraconazole for antifungal prophylaxis in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome

  • Original Article
  • Published:
Supportive Care in Cancer Aims and scope Submit manuscript

Abstract

Purpose

To compare the efficacy and safety of voriconazole with itraconazole as prophylaxis in leukemia patients.

Methods

Open-label, randomized study. Patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome undergoing induction chemotherapy or first salvage were eligible. Patients received voriconazole (400 mg intravenous (IV) every 12 h for two doses, followed by 300 mg BID) or itraconazole (200 mg IV twice daily for 2 days, followed by 200 mg IV daily).

Results

A total of 127 patients were enrolled. Four were excluded because they did not receive study drug (n = 3) or received two antifungal agents during the first week on study (n = 1), leaving 123 patients for analysis. None of the 71 patients receiving voriconazole developed proven or probable invasive fungal infection, compared to two (4%) of the 52 patients receiving itraconazole (P = 0.17). Drug discontinuation because of adverse events occurred in 15 patients (21%) receiving voriconazole and six (11%) receiving itraconazole (P = 0.23).

Conclusions

Voriconazole is a good alternative for prophylaxis in patients with leukemia. Elevated baseline bilirubin levels were associated with a higher risk of side effects in patients receiving IV voriconazole or IV itraconazole. Monitoring of liver function and drug levels should be considered for some patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Maertens J, Buve K, Anaissie E (2008) Broad-spectrum antifungal prophylaxis in patients with cancer at high risk for invasive mold infections: counterpoint. J Natl Compr Canc Netw 6:183–189

    PubMed  Google Scholar 

  2. van Burik JA (2005) Role of new antifungal agents in prophylaxis of mycoses in high risk patients. Curr Opin Infect Dis 18:479–483

    Article  PubMed  Google Scholar 

  3. Mattiuzzi GN, Alvarado G, Giles FJ, Ostrosky-Zeichner L, Cortes J, O'Brien S, Verstovsek S, Faderl S, Zhou X, Raad II, Bekele BN, Leitz GJ, Lopez-Roman I, Estey EH (2006) Open-label, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic malignancies. Antimicrob Agents Chemother 50:143–147

    Article  CAS  PubMed  Google Scholar 

  4. Mattiuzzi GN, Estey E, Raad I, Giles F, Cortes J, Shen Y, Kontoyiannis D, Koller C, Munsell M, Beran M, Kantarjian H (2003) Liposomal amphotericin B versus the combination of fluconazole and itraconazole as prophylaxis for invasive fungal infections during induction chemotherapy for patients with acute myelogenous leukemia and myelodysplastic syndrome. Cancer 97:450–456

    Article  CAS  PubMed  Google Scholar 

  5. Mattiuzzi GN, Kantarjian H, Faderl S, Lim J, Kontoyiannis D, Thomas D, Wierda W, Raad I, Garcia-Manero G, Zhou X, Ferrajoli A, Bekele N, Estey E (2004) Amphotericin B lipid complex as prophylaxis of invasive fungal infections in patients with acute myelogenous leukemia and myelodysplastic syndrome undergoing induction chemotherapy. Cancer 100:581–589

    Article  CAS  PubMed  Google Scholar 

  6. Mattiuzzi GN, Kantarjian H, O'Brien S, Kontoyiannis DP, Giles F, Zhou X, Lim J, Bekele BN, Faderl S, Cortes J, Pierce S, Leitz GJ, Raad I, Estey E (2004) Intravenous itraconazole for prophylaxis of systemic fungal infections in patients with acute myelogenous leukemia and high-risk myelodysplastic syndrome undergoing induction chemotherapy. Cancer 100:568–573

    Article  CAS  PubMed  Google Scholar 

  7. Denning DW, Ribaud P, Milpied N, Caillot D, Herbrecht R, Thiel E, Haas A, Ruhnke M, Lode H (2002) Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 34:563–571

    Article  CAS  PubMed  Google Scholar 

  8. Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, Kern WV, Marr KA, Ribaud P, Lortholary O, Sylvester R, Rubin RH, Wingard JR, Stark P, Durand C, Caillot D, Thiel E, Chandrasekar PH, Hodges MR, Schlamm HT, Troke PF, de Pauw B (2002) Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 347:408–415

    Article  CAS  PubMed  Google Scholar 

  9. Walsh TJ, Pappas P, Winston DJ, Lazarus HM, Petersen F, Raffalli J, Yanovich S, Stiff P, Greenberg R, Donowitz G, Schuster M, Reboli A, Wingard J, Arndt C, Reinhardt J, Hadley S, Finberg R, Laverdiere M, Perfect J, Garber G, Fioritoni G, Anaissie E, Lee J (2002) Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 346:225–234

    Article  CAS  PubMed  Google Scholar 

  10. Ascioglu S, Rex JH, de Pauw B, Bennett JE, Bille J, Crokaert F, Denning DW, Donnelly JP, Edwards JE, Erjavec Z, Fiere D, Lortholary O, Maertens J, Meis JF, Patterson TF, Ritter J, Selleslag D, Shah PM, Stevens DA, Walsh TJ (2002) Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 34:7–14

    Article  CAS  PubMed  Google Scholar 

  11. Pocock SJ, Simon R (1975) Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 31:103–115

    Article  CAS  PubMed  Google Scholar 

  12. Common Terminology Criteria for Adverse Events (CTCAE) (2003). In: Editor (ed)^(eds) Book Common Terminology Criteria for Adverse Events (CTCAE). DCTD, NCI, NIH, DHHS City. http://ctep.cancer.gov

  13. Riedel A, Choe L, Inciardi J, Yuen C, Martin T, Guglielmo BJ (2007) Antifungal prophylaxis in chemotherapy-associated neutropenia: a retrospective, observational study. BMC Infect Dis 7:70

    Article  PubMed  Google Scholar 

  14. Vehreschild JJ, Bohme A, Buchheidt D, Arenz D, Harnischmacher U, Heussel CP, Ullmann AJ, Mousset S, Hummel M, Frommolt P, Wassmer G, Drzisga I, Cornely OA (2007) A double-blind trial on prophylactic voriconazole (VRC) or placebo during induction chemotherapy for acute myelogenous leukaemia (AML). J Infect 55:445–449

    Article  PubMed  Google Scholar 

  15. Wingard JR, Carter SL, Walsh TJ, Kurtzberg J, Small TN, Gersten ID, Mendizabal AM, Leather H, Confer DL, Baden LR, Maziarz RT, Stadtmauer EA, Bolanos-Meade J, Brown J, DiPersio JF, Boeckh M, Marr KA (2007) Results of randomized, double-blind trial of fluconazole vs. voriconazole for the prevention of invasive fungal infections in 600 allogeneic blood and marrow transplant patients. Blood 110: abstract 163

    Google Scholar 

  16. Whittle AM, Ali S (2008) Primary prophylaxis with voriconazole in patients receiving induction chemotherapy on the MRC adult acute lymphoblastic leukaemia trial (UK-ALL XII) to avoid itraconazole-enhanced vinca neurotoxicity. Int J Laboratory Hematology 30:173–174

    Article  CAS  Google Scholar 

  17. Cordonnier C, Maury S, Pautas C, Bastie JN, Chehata S, Castaigne S, Kuentz M, Bretagne S, Ribaud P (2004) Secondary antifungal prophylaxis with voriconazole to adhere to scheduled treatment in leukemic patients and stem cell transplant recipients. Bone Marrow Transplant 33:943–948

    Article  CAS  PubMed  Google Scholar 

  18. Eiden C, Peyriere H, Cociglio M, Djezzar S, Hansel S, Blayac JP, Hillaire-Buys D (2007) Adverse effects of voriconazole: analysis of the French Pharmacovigilance Database. Ann Pharmacother 41:755–763

    Article  CAS  PubMed  Google Scholar 

  19. Lazarus HM, Blumer JL, Yanovich S, Schlamm H, Romero A (2002) Safety and pharmacokinetics of oral voriconazole in patients at risk of fungal infection: a dose escalation study. J Clin Pharmacol 42:395–402

    Article  CAS  PubMed  Google Scholar 

  20. Potoski BA, Brown J (2002) The safety of voriconazole. Clin Infect Dis 35:1273–1275

    Article  PubMed  Google Scholar 

  21. Lutsar I, Hodges MR, Tomaszewski K, Troke PF, Wood ND (2003) Safety of voriconazole and dose individualization. Clin Infect Dis 36:1087–1088

    Article  PubMed  Google Scholar 

  22. Pascual A, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O (2008) Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 46:201–211

    Article  CAS  PubMed  Google Scholar 

  23. Trifilio S, Ortiz R, Pennick G, Verma A, Pi J, Stosor V, Zembower T, Mehta J (2005) Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant 35:509–513

    Article  CAS  PubMed  Google Scholar 

  24. Tan K, Brayshaw N, Tomaszewski K, Troke P, Wood N (2006) Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities. J Clin Pharmacol 46:235–243

    Article  CAS  PubMed  Google Scholar 

  25. Boyd AE, Modi S, Howard SJ, Moore CB, Keevil BG, Denning DW (2004) Adverse reactions to voriconazole. Clin Infect Dis 39:1241–1244

    Article  PubMed  Google Scholar 

  26. Imhof A, Schaer DJ, Schanz U, Schwarz U (2006) Neurological adverse events to voriconazole: evidence for therapeutic drug monitoring. Swiss Med Wkly 136:739–742

    CAS  PubMed  Google Scholar 

  27. Zonios DI, Gea-Banacloche J, Childs R, Bennett JE (2008) Hallucinations during voriconazole therapy. Clin Infect Dis 47:e7–e10

    Article  CAS  PubMed  Google Scholar 

  28. Johnson LB, Kauffman CA (2003) Voriconazole: a new triazole antifungal agent. Clin Infect Dis 36:630–637

    Article  CAS  PubMed  Google Scholar 

  29. Trifilio S, Pennick G, Pi J, Zook J, Golf M, Kaniecki K, Singhal S, Williams S, Winter J, Tallman M, Gordon L, Frankfurt O, Evens A, Mehta J (2007) Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients. Cancer 109:1532–1535

    Article  CAS  PubMed  Google Scholar 

  30. Courtney R, Wexler D, Radwanski E, Lim J, Laughlin M (2004) Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults. Br J Clin Pharmacol 57:218–222

    Article  PubMed  Google Scholar 

  31. Gubbins PO, Krishna G, Sansone-Parsons A, Penzak SR, Dong L, Martinho M, Anaissie EJ (2006) Pharmacokinetics and safety of oral posaconazole in neutropenic stem cell transplant recipients. Antimicrob Agents Chemother 50:1993–1999

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Unit 428, Houston, TX, 77030, USA

    Gloria N. Mattiuzzi, Jorge Cortes, Srdan Verstovsek, Charles Koller, Sherry Pierce, Stefan Faderl & Hagop Kantarjian

  2. Department of Melanoma Medical Oncology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX, USA

    Gladys Alvarado

  3. Department of Pharmacy Clinical Program, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX, USA

    Deborah Blamble

  4. Department of Biostatistics, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX, USA

    Lianchun Xiao & Mike Hernandez

Authors
  1. Gloria N. Mattiuzzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jorge Cortes
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gladys Alvarado
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Srdan Verstovsek
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Charles Koller
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Sherry Pierce
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Deborah Blamble
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Stefan Faderl
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Lianchun Xiao
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Mike Hernandez
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Hagop Kantarjian
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gloria N. Mattiuzzi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mattiuzzi, G.N., Cortes, J., Alvarado, G. et al. Efficacy and safety of intravenous voriconazole and intravenous itraconazole for antifungal prophylaxis in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome. Support Care Cancer 19, 19–26 (2011). https://doi.org/10.1007/s00520-009-0783-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00520-009-0783-3

Keywords

Search

Navigation